In a new clinical trial that could affect Hodgkin lymphoma (HL) treatments, researchers have reported a 92 percent survival rate among advanced-stage patients receiving a new immunotherapy regimen, potentially eliminating the need for radiation therapy and reducing long-term side effects commonly associated with conventional treatments.
This is a significant advancement in the fight against a type of cancer that predominantly affects younger people and those older than 65.
